[Current trends in medical treatment of obliterating arteriopathies of the limbs].
D000109:Acetylcholine / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001920:Bradykinin / Q000037:antagonists & inhibitors; D004983:Ethanolamines / Q000627:therapeutic use; D005121:Extremities; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007093:Imidazoles / Q000627:therapeutic use; D011727:Pyridinolcarbamate / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use*
D004983:Ethanolamines; D005343:Fibrinolytic Agents; D006634:Histamine H1 Antagonists; D000960:Hypolipidemic Agents; D007093:Imidazoles; D014665:Vasodilator Agents; D011727:Pyridinolcarbamate; D000109:Acetylcholine; D001920:Bradykinin
Orientamenti attuali nella terapia medica delle arteriopatie obliteranti degli arti.